The OPT-CHF (OxyPurinol Therapy for CHF) study is designed to demonstrate the efficacy and safety of oral oxypurinol vs. placebo in a randomized, double-blind, twenty-four week trial in 400 patients in up to 50 centers. Measures of clinical efficacy (NYHA class and Patient Global Assessment) as well as clinical outcomes (e.g., death, worsening heart failure, and hospitalization) will be assessed as a composite endpoint in this trial.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
400
Carr-Dzindzio Cardiology
Oceanside, California, United States
Johns Hopkins University
Baltimore, Maryland, United States
Boston Medical Center
Boston, Massachusetts, United States
Saint Vincents Hospital and Medical Center
New York, New York, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.